Biomatter
Series A · $18M
Biomatter develops AI-powered computational technology to design custom enzymes tailored to specific chemical reactions and industrial applications.
About Biomatter
It has raised $18M in disclosed funding. FundFinder classes it as AI & ML.
Its investors also appear on FundFinder's most-active lists for Series A · B2B (81 funds), Series A · Generalist (63 funds), Series A · DeepTech (53 funds).
Company facts from Harmonic and public filings; team backgrounds from public profiles. Refreshed weekly.
Want the latest on Biomatter? Our research agent pulls the current
description, latest round and full investor base from public sources (about a minute).
Series A · $18M · Nov 2026
- Astanor Ventures — Europe's largest dedicated agrifood-tech impact investor with €800m+ AUM; its €360m second fund backs early-stage food, agriculture and biodiversity companies, and the portfolio of ~48 companies includes Infarm, Ynsect a
- Inventure — Nordic and Baltic early-stage firm with €230m+ under management, closing a €150m fourth fund in 2022; sweet spot of €1-3m first cheques. · cheques £300k – £5M